tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Larimar Therapeutics’ nomlabofusp shows therapeutic potential in FA

Larimar Therapeutics (LRMR) announced the publication of two peer-reviewed articles highlighting nonclinical data on the therapeutic potential, pharmacology, and mechanism of action of nomlabofusp as a novel frataxin protein replacement therapy designed to address the underlying cause of Friedreich’s ataxia, or FA. These data were included in the briefing package reviewed by the FDA in support of potentially using skin FXN concentrations as a reasonably likely surrogate endpoint for Larimar’s registrational program seeking accelerated approval for nomlabofusp.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1